Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989564
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organi ....State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organisations will considerably enhance the productivity of these researchers, increase their collaborative and scientific outputs and allow for training of students in the latest technologies. The facility will provide researchers with cutting-edge instrumentation for nationally and internationally important projects that would benefit human health.Read moreRead less
Of pets, vets and antimicrobials: fluoroquinolone use in dogs and resistance biology. Antimicrobial resistance is a current and growing threat relevant to human health, animal welfare, food production, and environmental preservation. This project will provide new insights into the basic science of antimicrobial resistance, through the generation of accurate data on the role of companion animal use of antibiotics on the development and control of resistance. Ultimate project goals are to produce ....Of pets, vets and antimicrobials: fluoroquinolone use in dogs and resistance biology. Antimicrobial resistance is a current and growing threat relevant to human health, animal welfare, food production, and environmental preservation. This project will provide new insights into the basic science of antimicrobial resistance, through the generation of accurate data on the role of companion animal use of antibiotics on the development and control of resistance. Ultimate project goals are to produce recommendations that limit the generation of further resistance. Project outcomes have demonstrable relevance to human preventative health, which is recognised as a national research priority. The health and welfare of pets will also be improved, which has associated community benefits.Read moreRead less
Mechanisms of chronic infection, immunotolerance and coevolution in avian circovirus infections. This project will generate fundamental new knowledge into the pathogenesis of persistent, chronic viral diseases in a wide range of animal hosts. Furthermore, beak and feather disease virus is listed as a Key Threatening Process under the Endangered Species Protection Act (1992) to at least sixteen endangered Australian bird species. Very little is known about the host-virus interactions that occur d ....Mechanisms of chronic infection, immunotolerance and coevolution in avian circovirus infections. This project will generate fundamental new knowledge into the pathogenesis of persistent, chronic viral diseases in a wide range of animal hosts. Furthermore, beak and feather disease virus is listed as a Key Threatening Process under the Endangered Species Protection Act (1992) to at least sixteen endangered Australian bird species. Very little is known about the host-virus interactions that occur during the early stages of infection or why some birds recover yet others develop full blown disease. This project will provide new knowledge that can be used to counteract its effects on current and future endangered species recovery program.Read moreRead less
Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and imp ....Antiviral compounds to inhibit the replicase of hepatitis C virus. Hepatitis C virus is a major public health problem. There are currently 200,000 infected individuals in Australia and 16,000 new infections every year. There is no specific treatment and current therapy treats a small percentage of patients only, which consists of interferon-alpha and ribavirin. This results in side effects and only a 50% cure rate. This study's outcomes are expected to lead to greater access to treatment and improved therapy resulting in higher cure rates and in a dramatic reduction in the cost of treating patients. A novel therapy will provide considerable benefits for the national biotechnology industry.Read moreRead less
The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in ....The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in order to study latent infection at the cellular level, and within infected monkeys. This will provide the first insights into the dynamics of latency - how these cells are produced and die - and should lead to novel approaches to controlling chronic infection.Read moreRead less
Design and Development of HIV-1 Integrase Inhibitors Based on a Natural Product Lead. HIV/AIDS is a significant health problem with over 40 million people infected with HIV worldwide. Resistance to current drugs is rising rapidly and new therapeutics are urgently needed. This project will bring together local expertise in organic synthesis and virology in order to develop new and better treatments for HIV/AIDS. Ultimately, Australians with HIV may benefit directly from anti-HIV compounds produce ....Design and Development of HIV-1 Integrase Inhibitors Based on a Natural Product Lead. HIV/AIDS is a significant health problem with over 40 million people infected with HIV worldwide. Resistance to current drugs is rising rapidly and new therapeutics are urgently needed. This project will bring together local expertise in organic synthesis and virology in order to develop new and better treatments for HIV/AIDS. Ultimately, Australians with HIV may benefit directly from anti-HIV compounds produced and may also benefit from advances in our understanding of this elusive virus resulting from the project.Read moreRead less
Structure-based discovery of anti-rotaviral agents. Rotavirus causes, particularly in children under 5 years of age, significant loss of life worldwide. Over 600,000 children under 5 years of age per annum die as a result of rotavirus infection. Australia records over 10,000 hospitalisations per annum due to rotavirus infection. This project aims, using structure-based drug design techniques, to develop inhibitors of a rotavirus protein that is essential in its lifecycle. These inhibitors may ....Structure-based discovery of anti-rotaviral agents. Rotavirus causes, particularly in children under 5 years of age, significant loss of life worldwide. Over 600,000 children under 5 years of age per annum die as a result of rotavirus infection. Australia records over 10,000 hospitalisations per annum due to rotavirus infection. This project aims, using structure-based drug design techniques, to develop inhibitors of a rotavirus protein that is essential in its lifecycle. These inhibitors may lead to the development of useful drugs to treat rotavirus infection and may reduce significant loss of life caused by this deadly virus.Read moreRead less
Structure-based discovery of anti-parainfluenza viral agents. Respiratory diseases, for example croup and bronchitis, in children are caused in the main by human parainfluenza viruses (hPIVs) types 1-3. No vaccines or specific antiviral therapy against hPIV infections exist. This project targets an essential protein in the virus' lifecycle. The essential triple role of the protein in virus spread makes it an attractive target for the development of hPIV-specific drugs. This project aims to prod ....Structure-based discovery of anti-parainfluenza viral agents. Respiratory diseases, for example croup and bronchitis, in children are caused in the main by human parainfluenza viruses (hPIVs) types 1-3. No vaccines or specific antiviral therapy against hPIV infections exist. This project targets an essential protein in the virus' lifecycle. The essential triple role of the protein in virus spread makes it an attractive target for the development of hPIV-specific drugs. This project aims to produce lead-like compounds that inhibit the protein's function and may provide novel drug candidates for further development. Furthermore the role of human host cell-associated carbohydrates in parainfluenza infection will be better understood.Read moreRead less
Evaluation of the potential of colostrum-derived anti-influenza antibody for the treatment and prevention of influenza. The project addresses a common disease problem, influenza, with a novel application of antibody technology. The technology may safely provide protection and cost effective treatment for those members of the community who are least protected by current approaches. The product can be cost-effective and readily available to enable the public to self medicate in high risk situation ....Evaluation of the potential of colostrum-derived anti-influenza antibody for the treatment and prevention of influenza. The project addresses a common disease problem, influenza, with a novel application of antibody technology. The technology may safely provide protection and cost effective treatment for those members of the community who are least protected by current approaches. The product can be cost-effective and readily available to enable the public to self medicate in high risk situations, or to be used as a public health tool in situtions to control outbreaks in those most susceptible to serious disease. The production system that enabled the creation of the technology is the advanced Australian dairy industry. Farmers with herds participating will receive a significant income benefit from, what was before, largely a waste product.Read moreRead less
Novel strategies in the design and development of antivirals against dengue virus. Globally, there are 50-100 million cases of dengue fever, with 500,000 cases of the more severe dengue haemorrhagic fever, each year. Australia has between 100 and 900 cases of dengue infection annually, often from travellers, but disease outbreaks occur in northern Australia. Effective anti-viral treatment will reduce disease burden. The project contributes to an evidence-based drug design program in collaboratio ....Novel strategies in the design and development of antivirals against dengue virus. Globally, there are 50-100 million cases of dengue fever, with 500,000 cases of the more severe dengue haemorrhagic fever, each year. Australia has between 100 and 900 cases of dengue infection annually, often from travellers, but disease outbreaks occur in northern Australia. Effective anti-viral treatment will reduce disease burden. The project contributes to an evidence-based drug design program in collaboration with Australia's leading biotechnology industries. As a biotechnology industry project developing treatments for an emerging disease, it contributes to the national research priorities of Frontier technologies for building and transforming Australian industries, Promoting and maintaining good health and Safeguarding Australia.Read moreRead less